溴隐亭联合二甲双胍治疗溴隐亭抵抗性泌乳素瘤患者的初步研究
该研究回顾性纳入2例溴隐亭抵抗性泌乳素瘤患者,其中1例合并糖耐量异常。联合二甲双胍治疗1年后泌乳素降至12 ng/mL、肿瘤明显缩小,月经恢复、溢乳消失并妊娠;单用溴隐亭14个月后泌乳素升至208 ng/mL、肿瘤复发(7 mm×8 mm×9 mm),再联合治疗2个月降至150 ng/mL。第2例联合治疗3个月后泌乳素降至2.08 ng/mL、睾酮显著升高、肿瘤缩小。作者认为该联合方案可能是抵抗性泌乳素瘤的新治疗选择。
要点
- 2例溴隐亭抵抗性泌乳素瘤患者接受溴隐亭联合二甲双胍治疗。
- 第1例联合治疗1年后泌乳素降至12 ng/mL、肿瘤明显缩小。
- 作者认为该联合方案可能是抵抗性泌乳素瘤的新治疗选择。
核心结论
- 作者认为,这2例病例支持二甲双胍与溴隐亭联合可能成为抵抗性泌乳素瘤新治疗的假设,但需要更多病例及对相关机制的进一步研究。
研究设计与样本
- 本研究为对2例溴隐亭抵抗性泌乳素瘤患者的回顾性回顾,其中第1例合并糖耐量异常并接受二甲双胍治疗,基于其发现招募了第2例溴隐亭抵抗性患者。
主要发现
- 第1例联合治疗1年后泌乳素降至12 ng/mL、肿瘤明显缩小,月经恢复、溢乳消失并妊娠,2016年8月分娩一健康男婴。
- 第1例产后仅用溴隐亭哺乳,单用溴隐亭14个月后泌乳素升至208 ng/mL、肿瘤复发(7 mm×8 mm×9 mm)。
- 第1例再次联合溴隐亭与二甲双胍治疗2个月后,泌乳素由208 ng/mL降至150 ng/mL。
- 第2例联合治疗3个月后泌乳素降至2.08 ng/mL、睾酮水平显著升高、肿瘤缩小。
局限性
- 作者指出需要更多病例及对相关机制的进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prolactinomas are the most common functional pituitary adenomas and dopamine agonists are the primary therapy. However, some patients are resistant to dopamine agonists. Recently, metformin has been proposed as a cancer treatment. CASE DESCRIPTION: This study is a retrospective review of 2 cases including 1 patient with prolactinoma who was resistant to bromocriptine, diagnosed with impaired glucose tolerance, and administered metformin. Surprisingly, combining the patient's treatment with metformin decreased prolactin (PRL) levels to 12 ng/mL and significantly decreased the size of the tumor after 1 year of combination therapy. As menstruation resumed and galactorrhea resolved, the patient became pregnant and stopped using metformin but continued taking bromocriptine. She gave birth to a healthy boy in August 2016. After delivery, she decided to breastfeed the baby and only took bromocriptine. After 14 months of using bromocriptine alone, her PRL level increased to 208 ng/mL and the tumor reappeared (7 mm × 8 mm × 9 mm). Interestingly, the patient's PRL level decreased from 208 ng/mL to 150 ng/mL 2 months after using combination treatment with bromocriptine and metformin. On the basis of these findings, a second bromocriptine-resistant patient was recruited. After 3 months of combined treatment with bromocriptine and metformin, the patient's PRL level decreased to 2.08 ng/mL, testosterone levels increased significantly, and the tumor size decreased. CONCLUSIONS: Although more cases and investigations into the mechanisms underlying these effects are needed, these 2 cases support the hypothesis that the combination of metformin and bromocriptine might be a new treatment for resistant prolactinomas.
引用
- Liu X, Liu Y, Gao J, et al. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study. World Neurosurg. 2018. PMID: 29530699. doi:10.1016/j.wneu.2018.02.188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。